In today’s recent session, 0.51 million shares of the Transmedics Group Inc (NASDAQ:TMDX) have been traded, and its beta is 2.13. Most recently the company’s share price was $66.76, and it changed around -$5.84 or -8.05% from the last close, which brings the market valuation of the company to $2.24B. TMDX at last check was trading at a discount to its 52-week high of $177.37, offering almost -165.68% off that amount. The share price’s 52-week low was $55.00, which indicates that the recent value has risen by an impressive 17.62% since then. We note from Transmedics Group Inc’s average daily trading volume that its 10-day average is 1.47 million shares, with the 3-month average coming to 2.05 million.
Transmedics Group Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.70. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 3 recommended TMDX as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Transmedics Group Inc is expected to report earnings per share of 0.15 for the current quarter.
Transmedics Group Inc (NASDAQ:TMDX) trade information
Instantly TMDX has been showing red trend so far today with a performance of -8.05% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 76.36 on recent trading dayincreased the stock’s daily price by 12.57%. The company’s shares are currently up 7.07% year-to-date, but still down -2.91% over the last five days. On the other hand, Transmedics Group Inc (NASDAQ:TMDX) is -7.98% down in the 30-day period. We can see from the shorts that 8.99 million shares have been sold at a short interest cover period of 3.54 day(s).
The consensus price target as assigned by Wall Street analysts is $109, which translates to bulls needing to increase their stock price by 38.75% from its current value. Analyst projections state that TMDX is forecast to be at a low of $90 and a high of $125.
Transmedics Group Inc (TMDX) estimates and forecasts
The year-over-year growth rate is expected to be 77.76%, up from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 109.49M in revenue for the current quarter. 6 analysts expect Transmedics Group Inc to make 119.4M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 81.17M and 96.85M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 34.88%. Forecasts for the next quarter put sales growth at 23.28%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 8.36%.
TMDX Dividends
Transmedics Group Inc’s next quarterly earnings report is expected to be released in March.
Transmedics Group Inc (NASDAQ:TMDX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.40% of Transmedics Group Inc shares, and 111.97% of them are in the hands of institutional investors. The stock currently has a share float of 115.91%. Transmedics Group Inc stock is held by 488.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 13.7063% of the shares, which is about 4.49 million shares worth $676.31 million.
BLACKROCK INC., with 8.0755% or 2.65 million shares worth $398.47 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Nov 30, 2024. The former held 2.16 shares worth $146.44 million, making up 6.43% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 1.02 shares worth around $69.19 million, which represents about 3.04% of the total shares outstanding.
